Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | BDKRB1 | P46663 | 11/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15372721 | 0.84 | BDKRB1 (0.57) | BDKRB1LMNA | |
| SCHEMBL5117768 | 0.83 | BDKRB1 (0.57) | BDKRB1KEAP1NFE2L2LMNAPTGDR2 | |
| SCHEMBL4476644 | 0.83 | BDKRB1 (0.56) | BDKRB1KDM4ELMNA | |
| SCHEMBL3996842 | 0.81 | CNR2 (0.47) | CNR2CNR1KDM4EEPHX2LMNA | |
| SCHEMBL3997059 | 0.80 | BDKRB1 (0.66) | BDKRB1EPHX2 | |
| SCHEMBL493487 | 0.78 | KEAP1 (0.52) | KDM4EKEAP1NFE2L2LMNA | |
| SCHEMBL4467178 | 0.77 | EPHX2 (0.40) | CNR2CNR1EPHX2PTGDR2 | |
| SCHEMBL4425672 | 0.77 | BDKRB1 (0.56) | BDKRB1EPHX2 | |
| SCHEMBL493253 | 0.74 | BDKRB1 (0.56) | CNR2BDKRB1KEAP1NFE2L2LMNA | |
| SCHEMBL700853 | 0.73 | BDKRB1 (0.62) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | CNR2 91/4885CNR1 160/4885BDKRB1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.